post-transplant antibody-mediated rejection
Conditions
Interventions
Rituximab is intravenously administered with single dose of 375mg/m2.
Sponsors
Tokyo Women's Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Sensitized cases before transplantation: Out patients and/or admitted patients. Positivity of antibody for HLA, and awaiting for the organ transplantation including liver, heart, pancreas/islet, or small intestine. Under fully informed consent with legal representative. Cases with AMR: Out patients and/or admitted patients. With ongoing AMR after organ transplantation including liver, heart, pancreas/islet, or small intestine. Under fully informed consent with legal representative.
Exclusion criteria
Exclusion criteria: The cases with active infection. The cases with viable malignancy, excluding hepatocellular carcinoma which is rescued by liver transplantation. Any cases which are considered as inadequate to entry the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitized cases: the incidence of negativity of antibody, or the change of antibody titer The cases with antibody-mediated rejection: organ function or pathological finding | — |
Countries
Japan
Contacts
Public ContactHiroto Egawa
Tokyo Women's Medical University Department of Surgery, Institute of Gastroenterology
Outcome results
None listed